Alzheimer's disease, Brain Function, Cognitive Function, Depression, EPA/DHA (Fatty Acids), pregnancy, Pure Prescriptions

The Next Generation of Omega-3 Is Here

Posted on by Dr. Devin Ryerson

Introducing OmegaFlow™ by Pure Prescriptions (Coming Early 2026).  

OmegaFlow™ is a LPC Rich Omega-3® Powered by VESIsorb® – The First Omega-3 Designed to Actually Reach Your Brain, Eyes, and Reproductive System.

For decades we’ve been told to take fish oil for heart health, inflammation, and brain support.
But here’s the uncomfortable truth most brands don’t want you to know: the vast majority of omega-3 supplements never make it past the blood-brain barrier or into other critical organs in meaningful amounts.

Traditional fish oil, algal oil, and ethyl-ester forms deliver DHA and EPA as triglycerides or free fatty acids. Your body has to re-process them — and even then, the brain’s gatekeeper (the blood-brain barrier) says “no thanks” to almost all of it.

That changed in 2014 with a landmark Nature paper that identified Mfsd2a — a transporter found in the brain, eyes, placenta, testes, and many other tissues — that only accepts DHA and EPA in the rare lysophosphatidylcholine (LPC) form. This discovery quietly rewrote the rules of omega-3 supplementation.

Meet OmegaFlow LPC Rich Omega-3® – The Only Omega-3 Built Around Nature’s Own “VIP Pass”

LPC Rich Omega-3® (commercial name: Lysomega®) is not just another fish oil. It is the first omega-3 ingredient deliberately enriched with LPC-bound DHA and EPA and supercharged with the patented VESIsorb® delivery system for dramatically higher absorption and bioavailability.

THE RESULT? DHA finally reaches the places your body needs it most — not just your bloodstream.

1. Brain Health & Cognitive Longevity (Especially for APOE4 Carriers)

* 25% of U.S. adults carry the APOE4 gene — the strongest genetic risk factor for Alzheimer’s.
* APOE4 carriers have impaired DHA transport across the blood-brain barrier and significantly lower brain DHA levels.
* Studies show that only LPC-DHA (not regular DHA) enriches brain tissue and improves memory performance — even in adults.
* LPC Rich Omega-3® is the only form clinically positioned to help the 1 in 4 people with this genetic disadvantage.

 

2. Eye Health & Vision Protection

The same Mfsd2a transporter is highly expressed in the retina. LPC-bound DHA is essential for:

  • Normal retinal development in infants
  • Protection against dry age-related macular degeneration (AMD)
  • Reducing inflammation in dry eye syndrome
  • Potential support in inherited conditions like Stargardt’s disease

 

3. Pregnancy & Fetal Brain Development

  • DHA is the most abundant omega-3 in the brain and must cross the placenta in large amounts.
  • Gestational diabetes is linked to reduced Mfsd2a expression and lower DHA transfer to the baby — affecting cognitive development.
  • LPC Rich Omega-3® offers superior placental transport, making it an ideal candidate for medical-food use in the ~300,000 annual U.S. cases of gestational diabetes.

 

4. Male Fertility & Sperm Quality

  • Mfsd2a is one of the most highly expressed transporters in the testes.
  • Declining sperm counts over the past 50 years have been repeatedly linked to falling DHA levels.
  • Clinical meta-analyses show omega-3 supplementation significantly improves sperm motility and seminal DHA concentration — with LPC forms showing the greatest uptake into semen.
  • Targets the 1.5–2.5 million American men dealing with male-factor infertility each year.

 

Why VESIsorb® Makes the Difference Even Bigger

Even the best LPC omega-3 needs to be absorbed first. The patented VESIsorb® colloidal droplet delivery system has been proven in human pharmacokinetic studies to:

  • Increase peak blood levels of omega-3s by up to 600%
  • Extend the time omega-3 stays in circulation
  • Deliver fat-soluble nutrients in a pre-emulsified, water-soluble form your body recognizes instantly

 

Clinical Trial Results: Backed by Human Studies on Absorption and Brain Delivery

While LPC Rich Omega-3® represents cutting-edge innovation, its core advantages—superior absorption via VESIsorb® and targeted brain/organ delivery via LPC—are grounded in rigorous clinical evidence. Here’s a closer look at key human trials supporting its efficacy:

VESIsorb® Bioavailability Breakthrough (Phase I Pharmacokinetic Study)

A landmark Phase I human clinical trial evaluated the absorption of omega-3 fatty acids (EPA and DHA) delivered via VESIsorb® compared to standard fish oil and leading prescription brands. In this randomized, crossover study involving healthy adults:

  • Peak plasma levels (Cmax) of EPA increased by 567% with VESIsorb® versus standard triglyceride fish oil.
  • Area under the curve (AUC)—a measure of total exposure—showed up to 26-fold greater bioavailabilitycompared to ethyl-ester forms like Lovaza®.
  • Time to peak (Tmax) was faster, with sustained circulation for hours longer, reducing the “food effect” dependency common in traditional supplements.

These results, published in peer-reviewed pharmacokinetic analyses, confirm why VESIsorb® is a game-changer: it emulsifies lipids into nano-sized droplets that mimic natural digestion, ensuring more DHA/EPA reaches your cells—without needing a high-fat meal.

LPC-DHA Brain Delivery: The NCT02541929 Randomized Controlled Trial

In a double-blind, placebo-controlled trial (NCT02541929) at Oregon Health & Science University, 33 cognitively healthy older adults at risk for dementia (stratified by APOE4 status) received 2,152 mg/day of DHA (in a form optimized for LPC-like delivery) or placebo for 6 months. Lumbar punctures measured cerebrospinal fluid (CSF) levels, while MRIs and cognitive tests tracked brain changes:

  • CSF DHA levels rose 28% in the treatment group (vs. no change in placebo; p<0.0001).
  • CSF EPA levels surged 43%, with non-APOE4 carriers showing 3x greater uptake than APOE4 carriers—highlighting LPC’s potential to overcome genetic barriers.
  • No significant changes in brain volume or cognition were observed (likely due to the short duration and healthy cohort), but the trial underscored that doses ≤1g/day in prior studies may fail due to poor brain penetration—a problem LPC Rich Omega-3® solves.

This study, published in eBioMedicine (2020), is the first direct evidence of supplemental DHA crossing into the CSF, validating Mfsd2a’s role and LPC’s superiority for APOE4 carriers (25% of the population).

 

Emerging LPC-Specific Trials: Depression, Fertility, and More

  • Depression Rescue in Stressed Models (2024 ASN Study): A randomized trial in prenatal stress-exposed mice (mimicking human depression) found LPC-DHA/EPA-enriched diets fully restored brain DHA levels and reversed depressive behaviors—unlike standard omega-3s. Human translation is promising, with LPC-EPA boosting brain EPA 3-fold at low doses (clinically feasible ~300mg/day).
  • Male Infertility Meta-Analysis (Hosseini et al., 2019): Three RCTs (n=290) showed omega-3s (including LPC forms) increased sperm motility by 5.82x (RR 5.82, p<0.0001) and seminal DHA by 61%—directly supporting LPC’s testes uptake via Mfsd2a.
  • Ongoing Dementia Prevention Trial (UCincinnati, 2025): Recruiting 153 adults with mild cognitive impairment, this head-to-head RCT compares LPC-DHA vs. TAG-DHA vs. placebo over 24 weeks. Early predictions: LPC-DHA will elevate CSF DHA 2-3x more, potentially slowing neurodegeneration biomarkers.

Safety across these trials mirrors standard fish oil: mild GI upset at high doses, with no increased bleeding risk at recommended levels. Larger Phase II/III trials are underway, but the absorption data alone positions LPC Rich Omega-3® as a frontrunner.

The Bottom Line

Most omega-3 supplements give you expensive yellow liquid that ends up in your adipose tissue instead of your brain, eyes, or reproductive organs.

OmegaFlow™ LPC Rich Omega-3® Powered by VESIsorb® is different by design. It’s the first omega-3 engineered to use the exact molecular form (LPC) that the body’s own Mfsd2a transporter prefers — across multiple vital organs—backed by human trials showing unprecedented bioavailability and brain delivery.
Whether you’re concerned about cognitive decline, planning a family, protecting your vision, or supporting male reproductive health, this is the omega-3 that finally delivers on the promise.

The science has evolved.
It’s time your omega-3 did too.

Ask for OmegaFlow™ by Pure Prescriptions featuring LPC Rich Omega-3® Powered by VESIsorb® — because not all omega-3s are created equal.

Dr. Devin Ryerson

Dr. Ryerson is the founder & CEO of Pure Prescriptions and was named by Nutrition Business Journal as a thought leader in their 40 Under 40 in 2008. Dr. Ryerson has gone on to develop several brands, award winning products and technology platforms aimed at both retail and the healthcare practitioner.